Finance

Mga Listahan
Bakit tumaas ang REGN 3.35%?
Tingnan ang Higit pang Detalye
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
$778.36
+3.35%
(+25.24) 1D
$782.54
+0.54% (+4.17)
Pagkalipas ng oras ng trabaho
Sarado: Okt 14, 4:00:01 PM GMT-4  ·   USD
Lahat ng simbolo
SimboloPresyoPalitan% ng Pagbabago
Bumubuo ng mga nangungunang insight para sa REGN...
Buksan
$758.16
Mataas
$781.84
Mababa
$755.21
Mkt. cap
80.14B
Avg. na dami
706.16K
Dami
0.00
Dividend
0.48%
Bawat tatlong buwang dividend
$0.94
Petsa ng ex-dividend
Ago 18, 2026
P/E ratio
19.24
Mataas nang 52-wk
$859.34
Mababa nang 52-wk
$564.00
EPS
$40.45
Beta
0.16
Mga natitirang share
101.14M
Bilang ng mga empleyado
15K
Buksan
$758.16
Mataas
$781.84
Mababa
$755.21
Mkt. cap
80.14B
Avg. na dami
706.16K
Dami
0.00
Dividend
0.48%
Bawat tatlong buwang dividend
$0.94
Petsa ng ex-dividend
Ago 18, 2026
P/E ratio
19.24
Mataas nang 52-wk
$859.34
Mababa nang 52-wk
$564.00
EPS
$40.45
Beta
0.16
Mga natitirang share
101.14M
Bilang ng mga empleyado
15K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
Tungkol sa Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Mga Empleyado15.3K
Itinatag1988
HeadquartersTarrytown, New York, Estados Unidos
Sektor-
Mga rating ng analyst
Batay sa 22 (na) analyst na nagbigay ng mga rating ng stock sa REGN sa nakalipas na 3 buwan
Pagbili
Pagbili
14
Pag-hold
8
Pagbebenta
0
12 buwang forecas
Batay sa 22 (na) analyst sa Wall Street na nag-aalok ng mga target na presyo sa loob ng 12 buwan para sa REGN sa nakalipas na 3 buwan.
Pinakamataas
Kasalukuyan $778.36
$1,030.00 (+32.33%)
Average
$867.86 (+11.50%)
Pinakamababa
$740.00 (-4.93%)
Analyst
Rekomendasyon
Aksyon
Target na presyo
Inaasahan
Petsa
Unknown Analyst
UBS
Buy
Upgraded
$978.00
+25.6%
10/14/2026
Joon Lee
Truist Financial
Buy
Initiated
$978.00
+25.6%
10/14/2026
Louise Chen
Scotiabank
Hold
Maintained
$770.00
-1.1%
10/14/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$920.00
+18.2%
10/12/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$908.00
+16.7%
10/12/2026
Geoff Meacham
Citi
Hold
Maintained
$740.00
-4.9%
10/12/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$810.00
+4.1%
10/08/2026
Gregory Renza
Truist Financial
Buy
Maintained
$780.00
+0.2%
10/07/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
$779.00
+0.1%
10/07/2026
Chris Schott
J.P. Morgan
Buy
Reiterated
$950.00
+22.1%
10/06/2026
Brian Skorney
Robert W. Baird
Hold
Maintained
$761.00
-2.2%
10/02/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$972.00
+24.9%
10/01/2026
David Risinger
Leerink Partners
Hold
Maintained
-
-
10/02/2026
Biren Amin
Piper Sandler
Buy
Maintained
$854.00
+9.7%
10/02/2026
Eliana Merle
Barclays
Buy
Maintained
$917.00
+17.8%
10/02/2026
Akash Tewari
Jefferies
Buy
Maintained
$930.00
+19.5%
10/01/2026
Jasper Hellweg
Argus Research
Buy
Upgraded
$850.00
+9.2%
09/30/2026
Mohit Bansal
Wells Fargo
Hold
Maintained
$750.00
-3.6%
09/28/2026
Eve Burstein
Bernstein
Hold
Maintained
$756.00
-2.9%
09/25/2026
Rajesh Kumar
HSBC
Buy
Maintained
$920.00
+18.2%
09/10/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$1,030.00
+32.3%
08/03/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
$795.00
+2.1%
07/30/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
$960.00
+23.3%
07/30/2026
John Newman
Canaccord Genuity
Buy
Maintained
$875.00
+12.4%
07/22/2026
Alexandria Hammond
Wolfe Research
Buy
Reiterated
$860.00
+10.5%
05/18/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$825.00
+6%
05/18/2026
Nicholas Lorusso
TD Cowen
Buy
Maintained
$960.00
+23.3%
05/06/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$865.00
+11.1%
04/30/2026
William Pickering
Bernstein
Buy
Maintained
$921.00
+18.3%
04/08/2026
Christopher Raymond
Raymond James
Buy
Maintained
$870.00
+11.8%
01/30/2026
Huling ulat
Hul 30, 2026
Fiscal period
Q2 2026
$14.29 / $10.21
+39.99%lumampas
Kita / Pagtataya (USD)
4.29B / 3.82B
+12.22%lumampas
Earnings call para sa Fiscal Q2 2026
Hinihintay ang earnings call
Sa isang sulyap
Mga insight mula sa mga pinakabagong balita at ulat
Mga nakaraang ulatLahat ng value sa USD
Loading Previous Earnings...
Kita
Net na kita
Lahat ng value sa USD
Set 2025
Dis 2025
Mar 2026
Hun 2026
Kita
3.75B
3.88B
3.61B
4.29B
Gastusin sa mga naibentang produkto
2.00B
2.21B
2.21B
2.21B
Halaga ng kita
2.00B
2.21B
2.21B
2.21B
Mga gastos sa pananaliksik at pag-develop
-
-
-
-
Kabuuang gastos sa pananaliksik at pag-develop
-
-
-
-
Mga gastos sa pagbebenta, pangkalahatan, at admin
657.80M
775.00M
647.70M
662.10M
Gastos sa pagpapatakbo
647.80M
775.00M
647.70M
662.10M
Kabuuang gastos sa pagpapatakbo
2.64B
2.99B
2.86B
2.87B
Kita sa pagpapatakbo
1.11B
898.60M
744.80M
1.42B
Iba pang hindi kita sa pagpapatakbo
3.00M
958.50M
-7.30M
100.00K
EBT na may mga hindi karaniwang item
1.76B
1.04B
831.20M
1.53B
EBT na hindi kasama ang mga hindi karaniwang item
1.27B
2.04B
908.10M
1.59B
Gastos sa buwis sa kita
303.30M
199.10M
104.00M
230.90M
Epektibong rate ng buwis
17.20%
19.08%
12.51%
15.11%
Iba pang gastos sa pagpapatakbo
-10.00M
-
-
-
Net na kita
1.46B
844.60M
727.20M
1.30B
Margin ng kabuuang kita
38.89%
21.74%
20.17%
30.23%
Kita bawat share
11.83
11.44
9.47
14.29
Kita sa interes at investment
175.10M
193.30M
183.50M
183.30M
Gastos sa interes
-19.30M
-12.20M
-12.90M
-11.00M
Mga net na gastos sa interes
155.80M
181.10M
170.60M
172.30M
Mga singil sa depreciation at amortization
-
-
-
-
EBITDA
1.25B
1.04B
868.00M
1.54B
Kita o pagkalugi mula sa pagbebenta ng mga asset
-
-
-
-
Mga transaksyon ng insider
Kinukuha ang data ng mga insider na transaksyon mula sa mga third-party na source. Matuto pa
Insider
Posisyon
Uri
Petsa
Mga Share
Halaga
Page 1
Posibleng magkaroon ng mga pagkakamali ang AI content. Matuto pa
Mga app ng Google